Previous 10 | Next 10 |
Amneal Pharmaceuticals, Inc. (the “ Company ”) (NYSE:AMRX) and Kashiv BioSciences LLC (“ Kashiv ”) today announced they have entered into a definitive agreement under which Amneal Pharmaceuticals LLC (“ Amneal ”), a wholly-owned subs...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) announced that it has received approval of an additional strength of 500 mg to its Abbreviated New Drug Application (ANDA), from the U.S. Food and Drug Administration (FDA) for Abiraterone ...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the “Company”) today announced that Chirag Patel, Amneal’s Co-Chief Executive Officer and President, will present at the 39 th Annual J.P. Morgan Healthcare Conference on January 13, 2021 at 2:50 PM Eastern Time. A live...
The FDA has approved Amneal Pharmaceuticals' ([[AMRX]]) Abbreviated New Drug Application ((ANDAs)) for Acyclovir Cream, 5% a generic version of Zovirax for treatment of recurrent herpes labialis (cold sores) in immunocompetent adults and adolescents 12 years and older.The product is...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal”) today announced that it has received approval for its Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Acyclovir Cream, 5%. Acyclovir Cream, 5%, is the generic version of Zovir...
Image source: The Motley Fool. Amneal Pharmaceuticals, Inc. (NYSE: AMRX) Q3 2020 Earnings Call Nov 6, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Amneal Pharmaceuticals, Inc. (AMRX) Q3 2020 Earnings Call Transcr...
Amneal Pharmaceuticals, Inc. (AMRX) Q3 2020 Earnings Conference Call November 06, 2020 08:30 AM ET Company Participants Tasos Konidaris - Chief Financial Officer Chirag Patel - Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Conference Call Participants David Amsellem - P...
The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2020 Q3 - Results - Earnings Call Presentation
Amneal Pharmaceuticals (AMRX): Q3 Non-GAAP EPS of $0.16 beats by $0.04; GAAP EPS of -$0.06 misses by $0.05.Revenue of $519.29M (+37.3% Y/Y) beats by $37.07M.Press Release For further details see: Amneal Pharmaceuticals EPS beats by $0.04, beats on revenue
‒ Q3 2020 Net Revenue of $519 million; GAAP Net Loss of $(9) million; Diluted Loss per Share of $(0.06) ‒ ‒ Q3 2020 Adjusted Net Income (1) of $49 million; Adjusted EBITDA (1) of $114 million; Adjusted Diluted EPS (1) of $0.16‒ ...
News, Short Squeeze, Breakout and More Instantly...
Amneal Pharmaceuticals Inc. Class A Company Name:
AMRX Stock Symbol:
NASDAQ Market:
Amneal Pharmaceuticals Inc. Class A Website:
First presentation of preservative-free potassium phosphates in a single-dose IV infusion bag Third 505(b)(2) injectable added this year – will launch in third quarter Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) to...
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its second quarter 2024 financial results on Friday, August 9, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time. ...
FOCINVEZ (fosaprepitant) 150 mg/50 mL single dose vial is an anti-nausea agent for highly emetogenic and moderately emetogenic chemotherapy (HEC and MEC) Second injectable RTU product launched by Amneal in 2024 Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal”...